Compare DAO & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | MPLT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2025 |
| Metric | DAO | MPLT |
|---|---|---|
| Price | $17.97 | $11.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 38.1K | ★ 1.3M |
| Earning Date | 05-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $9.10 |
| 52 Week High | $18.94 | $40.43 |
| Indicator | DAO | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 66.06 | 28.18 |
| Support Level | $9.29 | $9.10 |
| Resistance Level | N/A | $20.73 |
| Average True Range (ATR) | 1.01 | 1.49 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 70.86 | 35.72 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.